<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> is essential for <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumor</z:e> growth </plain></SENT>
<SENT sid="1" pm="."><plain>This has been documented for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, and there is an emerging evidence suggesting that <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> of hematolymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> also depends on the induction of new blood vessel formation </plain></SENT>
<SENT sid="2" pm="."><plain>The most important proangiogenic agent is vascular endothelial growth factor (VEGF), activating VEGF receptors 1 and 2 </plain></SENT>
<SENT sid="3" pm="."><plain>The available data on <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in hemato-lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, such as <z:hpo ids='HP_0002488'>acute leukemias</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, and <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, point towards the significance of autocrine and paracrine VEGF-mediated effects for proliferation and survival of <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells in addition to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vascularization </plain></SENT>
<SENT sid="4" pm="."><plain>Antiangiogenic strategies have become an important therapeutic modality for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Several antiangiogenic agents targeting VEGF-related pathways are also being utilized in clinical trials for the treatment of hemato-lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, and in some instances these pathways have emerged as promising therapeutic targets </plain></SENT>
<SENT sid="6" pm="."><plain>This review summarizes recent advances in the basic understanding of the role of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in hemato-lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and the translation of such basic findings into clinical studies </plain></SENT>
</text></document>